Biosimilars explained – what is a biosimilar and should I prescribe them in practice?

Learning objectives:

  • What is a biologic and a biosimilar? Consider the complexity of biologics and how biosimilars are different from generic medicines. How is a biosimilar different from the reference biologic, and how this compares with batch-to-batch variations within the reference medicine
  • How are biosimilars developed? Consider the different stages including the comparative quality, non-clinical and non-clinical studies
  • How are biosimilars approved? Consider EMA’s approval process and their experience of biosimilars
  • What is NICE’s guidance on biosimilars implementation? Article: nice.org.uk/guidance/ktt15
  • Why should we use biosimilars? Consider the potential cost saving and the opportunity to improve access for new innovative medicines

This session is organised and remunerated by Mylan

Thursday 15th November 2018

12:05 - 12:35

Primary, Community & Specialist Care

Prescribing Icon

Speakers

GP Partner & Medical Education & Scottish Lead, North Berwick Health Centre, GPwSI Diabetes, Primary Care Diabetes Society

Our site is intended for UK Healthcare Professionals

Are you a UK Healthcare Professional?

We’re sending you to our partner charity’s site. 

DRWF provide information and support for people with diabetes and their friends & families